OsteoProtect
Treatment of osteoporosis by inhibitors of sphingosine-1-phosphatase (S1P)-lyase.
Novel approach for treating reduced bone density/stability
Specific inhibitors identified
In vivo data available
Pharmacological therapy for osteoporotic fractures.
The inventors showed that S1P inhibited osteoclast function, but most importantly, stimulated osteoblasts to produce new bone. Thus, a sufficient S1P-concentration is fundamental for an osteoanabolic fine-tuning of the skelettal system. Furthermore they showed that high S1P counteracts obesity by reducing adipose tissue mass. According to the invention, in patients suffering from osteoporosis, bone formation may be facilitated (and obesity reduced) by administering inhibitors of the S1P-lyase (the key enzyme degrading S1P). An exemplary S1P-lyase inhibitor tested by the inventors is the compound 4deoxypyridoxin (DOP).
Licensing
07/03/2019 00:00:00
WO2019EP55667 20190307
- international:
A61K31/417; A61K31/4415; A61K31/4439; A61P19/10; A61P3/06; A61P3/08
- cooperative:
A61K31/417 (EP); A61K31/4415 (EP); A61K31/4439 (EP); A61P19/10 (EP); A61P3/06 (EP); A61P3/08 (EP)
Patent application
4955
德国
